by Growing Prevalence of Inflammatory Bowel Diseases to Aid Market Growth
Inflammatory bowel disease is highly prevalent around several regions of the world and often affects the quality of life among patients. The growing prevalence of inflammatory bowel disease has compelled healthcare experts around the world to aggressively work toward the discovery of effective and in-vitro inflammatory bowel disease diagnostics due to which, the global in-vitro inflammatory bowel disease diagnostics market has witnessed considerable movement over the past few years. In-vitro inflammatory bowel disease diagnostics primarily relies on endoscopy– an invasive procedure wherein anesthesia and bowel preparation is required. Although endoscopy has largely remained a go-to medical procedure, the negative effect on the patient’s quality of life continues to remain a major challenge.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111850
In the wake of these existing challenges, a range of new technologies and advancements, including in-vitro inflammatory bowel disease diagnostics is currently gaining considerable adoption. The recent advancements in positron emission tomography (PET), especially with the use of antibody-conjugated tracers, have offered promising results, while treating inflammatory bowel disease, a factor that is expected to propel the growth of the global in-vitro inflammatory bowel disease diagnostics market during the assessment period.
Research & Development Activities to Remain Pivotal for Global Market
Due to the growing prevalence of inflammatory bowel diseases, novel biologics are steadily being developed across laboratories and hitting clinics around the world. As players involved in the current in-vitro inflammatory bowel disease diagnostics market landscape are increasingly focusing on gaining approval of the FDA, the race toward discovering the most efficient and cost-effective in-vitro inflammatory bowel disease diagnostics continues to shift gears. In addition, as healthcare providers are increasingly emphasizing on improving the overall well-being of the patient, with it, efforts to improve in-vitro inflammatory bowel disease diagnostics continue to grow at a rapid pace. Research and development activities are projected to play a key role in the overall growth of the global in-vitro inflammatory bowel disease diagnostics market during the assessment period. At the moment, researchers around the world are increasingly leveraging high throughput in-vitro assays to discover the most effective compounds. The safety, longevity, and overall effectiveness of these compounds are being tested to minimize the prevalence of inflammatory bowel diseases.
Get a glimpse of the in-depth analysis through our Report Brochure
While researchers continue to take steps to improve the efficacy of in-vitro inflammatory bowel disease diagnostics, scientists are also focusing on minimizing research expenses.
Growing Adoption of Biomarkers and Analyzers to Fuel Market Growth
The growing prevalence of Crohn’s disease (CD) and ulcerative colitis (UC) in several regions of the world has played a key role in boosting the adoption of biomarkers and analyzers, which, in turn, is expected to propel the growth of the global in-vitro inflammatory bowel disease diagnostics market during the assessment period. The demand for predictive biomarkers has witnessed consistent growth as the need to efficiently assess the mucosal disease activity in inflammatory bowel diseases has become imperative. Serum-based biomarkers have gained considerable traction across the global in-vitro inflammatory bowel disease diagnostics market in recent times and as per current observations, this trend is likely to provide a considerable push to the growth of the market for in-vitro inflammatory bowel disease diagnostics.
Demand to Remain Sluggish amid COVID-19 Pandemic
The healthcare sector has arguable remained one of the busiest core sectors during the ongoing COVID-19 pandemic, as researchers, scientists, and other stakeholders in the healthcare sector are increasingly focusing on discovering vaccines to contain the novel coronavirus. The progress in in-vitro inflammatory bowel disease diagnostics has remained relative slower. Although research and development activities are expected to continue during the ongoing pandemic, the adoption of in-vitro inflammatory bowel disease diagnostics is expected to remain sluggish, particularly in 2020 due to the fear among patients pertaining to contracting the novel coronavirus in hospitals.
Analysts’ Viewpoint
The global in-vitro inflammatory bowel disease diagnostics market is expected to expand at a CAGR of ~4% during the forecast period. The market growth can be attributed to factors, including growing prevalence of inflammatory bowel diseases around the world, research and development activities, technological advancements, growing interest and adoption of minimally invasive procedures, and increasing emphasis on improving patient well-being. While the market growth will remain slower than initial projections in 2020 due to the ongoing COVID-19 pandemic, the market is expected to show signs of recovery during the last quarter of 2020.
In-vitro Inflammatory Bowel Disease Diagnostic Market: Overview
Inflammatory bowel disease (IBD) is a chronic disease, which is used to describe disorders that involve chronic inflammation of the digestive tract. Types of IBD include ulcerative colitis and Crohn’s disease.
Fecal and serologic biomarkers can be used in the diagnosis and management of inflammatory bowel disease (IBD). Fecal markers, such as calprotectin and lactoferrin have been studied for their ability to identify patients with IBD, assess disease activity, and predict relapse.
High prevalence of IBD boosts the in-vitro inflammatory bowel disease diagnostic market. In Europe, it is estimated that around 2.5 to 3 million people are affected by inflammatory bowel disease per year.
In-vitro Inflammatory Bowel Disease Diagnostic: Market Drivers
According to CDC data, in 2015, an estimated 1.3% of adults in the U.S., which is around 3 million reported being diagnosed with IBD, either Crohn’s disease or ulcerative colitis. Highest incidence and prevalence of IBD is observed in Scandinavia and the U.K. Incidence of Crohn’s disease in Europe ranges from 0.5 to 10.6 cases per 100,000 people per year, while incidence of ulcerative colitis ranges from 0.9 to 24.3 per 100,000 persons per year.
According to IBD Support Australia Incorporated, around 61,000 people in Australia are affected by inflammatory bowel disease of which, around 28,000 people are affected by Crohn’s disease and 33,000 are affected by ulcerative colitis
Rise in Demand for Less-invasive, Resource-benefit, and Cost-effective Diagnostic Modalities
Diagnostic and prognostic features of IBD are usually based on a combination of clinical, laboratory tests, radiology, endoscopy, and pathology aspects. Laboratory biomarkers are noninvasive or micro-invasive indices that are more rapid and cost less as compared to other techniques, thus relieving physiological and financial burden for patients. The use of biomarkers for diagnosis and management of IBD is still necessary. Descriptions of immunological pathway abnormalities in IBD improve assessment to identify the patient’s disease status, and relative risk of progression to complicated disease behaviors, and this information may ultimately influence therapeutic decisions.
Hence, high availability, easy access, high awareness, and cost-effectiveness provide in-vitro inflammatory bowel disease diagnostic a cutting edge over other options
Market Segmentation: In-vitro Inflammatory Bowel Disease Diagnostic Market
In terms of product, the global in-vitro inflammatory bowel disease diagnostic market has been divided into assays/biomarker and analyzers. The assays/biomarker segment has been further subdivided into calprotectin, lactoferrin, bile acids, h. pylori sa, pancreatic elastase, and others.
Based on end user, the global in-vitro inflammatory bowel disease diagnostic market has been classified into diagnostic laboratories, hospitals, and research institutes
Each of the segments has been analyzed in detail for in-vitro inflammatory bowel disease diagnostic market trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The in-vitro inflammatory bowel disease diagnostic market report provides current and future value (US$ Mn) for each of these segments for the period from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2030, along with market size estimations.
Regional Overview: In-vitro Inflammatory Bowel Disease Diagnostic Market
In terms of region, the global in-vitro inflammatory bowel disease diagnostic market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
High prevalence of diseases and well-established healthcare infrastructure that enables proper diagnosis of inflammatory bowel disease are responsible for high market share of the region. According to a paper published in Gastroenterology & Hepatology journal, in 2017, there were 6.8 million cases of inflammatory bowel disease globally, and the highest prevalence rate in 2017 occurred in high-income North America.
The current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the report for the period from 2018 to 2030, along with their CAGRs for the period from 2020 to 2030
The study also offers a list of recommendations, highlights, and useful insights of the market, which will help new companies willing to enter the market and existing companies to increase market share and in the decision-making process
Major Players
The report concludes with the company profiles section that includes key information about the major players in the in-vitro inflammatory bowel disease diagnostic market
Leading players analyzed in the report are
- DiaSorin S.p.A
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers AG
- Abbott
- Quidel Corporation
- American Laboratory Products Company (ALPCO)
- Certest Biotec SL.
- Biosystems S.A.
Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments
Key Questions Answered in In-vitro Inflammatory Bowel Disease Diagnostic Market Report
- What is the sales/revenue generated by in-vitro inflammatory bowel disease diagnostic products across all regions during the forecast period?
- What are the opportunities in the global in-vitro inflammatory bowel disease diagnostic market?
- What are the major drivers, restraints, opportunities, and threats in the global market?
- Which region is set to expand at the fastest CAGR during the forecast period?
- Which product segment is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
In-vitro Inflammatory Bowel Disease Diagnostic Market – Segmentation
Product
- Assays/Biomarker
- Analyzers
End User
- Diagnostic Laboratories
- Hospitals
- Research Institute
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111850/2900
